Login to Your Account



CV Therapeutics Banks $175M in Royalties Deal for Lexiscan

By Donna Young


Thursday, April 17, 2008
Shares of CV Therapeutics Inc. rose 17.6 percent Wednesday on news that the firm received $175 million in cash from New York-based investment firm TPG-Axon Capital in exchange for rights to 50 percent of royalties on North American sales of Lexiscan (regadenoson) injection. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription